TECH CENTER 1600/2900

Please type a plus sign (+) inside this box -

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to re

TRANSMITTAL **FORM**

(To be used for all correspondence after initial filing)

95	pond to a collection of information unles	ss it displays a valid OMB control number.		
	Application Number	09/922,378		
	Filing Date	August 3, 2001		
	First Named Inventor	William A. Horne		
	Group Art Unit	Not Yet Assigned		
	Examiner Name	Not Yet Assigned		
	Attorney Docket No.	480140.428D3		

ENCLOSURES (check all that apply)							
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s Extension of Time Request Express Abandonment Request Information Disclosure Statement; Form PTO-1448 Cited References Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.5	Assignment Papers (for an Application) Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer	CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Postcard Additional Enclosure(s) (please identify below):					
Remarks							
SIGNAT	URE OF APPLICANT, ATTORNEY,	OR AGENT					
Individual Name William T. Christiansen, Ph.D. 00500 PATENT TRADEMARK OFFICE Date							
	, , , , , , ,						
	CERTIFICATE OF MAILING						
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.							
Typed or printed name Na	Typed or printed name Nathan Adderson						
Signature	Jaka All	Date: 10/11/0/					





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

William A. Horne and Tilman Oltersdorf

RECEIVED

Application No.

09/922,378

OCT 1 7 2001

Filed For : August 3, 2001

HUMAN BAD POLYPEPTIDES, ENCODING

TECH CENTER 1600/2900

NUCLEIC ACIDS AND METHODS OF USE

Docket No.

: 480140.428D3

Date

: October 10, 2001

Commissioner for Patents Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the 14 references set forth on the attached Form PTO-1449. This application is a divisional and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/376,154 filed August 17, 1999; which is a divisional of Application No. 08/717,123, filed September 20, 1996. The references listed on the attached Form PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request.

As to any reference made of record on the attached Form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is

believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

William T. Christiansen, Ph.D.

Registration No. 44,614

WTC:nka

Enclosures:

Postcard Form PTO/SB/21 Form PTO-1449

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

D:\NrPortbl\iManage\NATHANA\222556_1.DOC

FOMALL DATE CAN ELLUE PPARTMENT OF COMMERCE (REV.7-80)

ATTY, DOCKET NO. 480140.428D3 APPLICATION NO. 09/922,378

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

William A. Horne and Tilman Oltersdorf

FILING DATE GROUP ART UNIT

FILING DATE
August 3, 2001

GROUP ART UNIT
Not Yet Assigned

ZII	PATEN	TDO	CUN	TENTS
		1 1/1/2		

U.S. I ATENT DOCUMENTS								
*EXAMINER !NITIAL	DOCUMENT NUMB		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
-	AA	4,683,195	7/28/87	Mullis et al.	435	6		
•	AB	4,683,202	7/28/87	Mullis	435	91.2	TECH	
	AC	4,754,065	6/28/88	Levenson et al.	562	564		
	AD	4,800,159	1/24/89	Mullis et al.	435	91.2		
	AE	5,352,771	10/4/94	Kostic et al.	530	345		
	AF	5,663,316	9/2/97	Xudong	536	23.5	1600/290	
**	AG						8	

FOREIGN PATENT DOCUMENTS

TRANSLATION								ATION
		DOCUMENT NUMBER	DATE		COUNTRY		YES	NO
	АН	WO 96/13614	5/9/96	WIPO				
	AI							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)
Gyuris et al., "Cdil, a Human G1 and S Phase Protein Phosphates That Associates with Cdk2," Cell 75: 791-803, 1993.
Ruden et al., "Generating Yeast Transcriptional Activators Containing No Yeast Protein Sequences," <i>Nature 350</i> : 250-252, 1991.
Sato et al., "Interactions Among Members of the Bcl-2 Protein Family Analyzed with a Yeast Two-Hybrid System," <i>Proc. Natl. Acad. Sci. USA 91</i> : 9238-9242, 1994.
Sinkovics et al., "Apoptosis by Genetic Engineering," Leukemia 8(1): S98-S102, 1994.
Ross et al., "Gene Therapy in the United States: A Five-Year Status Report," Human Gene Therapy 7: 1781-1790, 1996.
Wolff et al., "Direct Gene Transfer into Mouse Muscle in Vivo," <i>Science 247</i> : 1465-1468, 1990.
Yang et al., "Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death," <i>Cell 80</i> : 285-291, January 27, 1995.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).